Moderna publishes presentation on phase I intismeran study in resected pancreatic cancer

Bitget2026/10/25 13:32

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Moderna published phase I study results for adjuvant intismeran autogene with FOLFIRINOX in 20 patients with resected pancreatic ductal adenocarcinoma.
Neoantigen-specific T-cell responses were detected in all 19 evaluable patients, including during concurrent chemotherapy.
At median follow-up of approximately 17 months, 11 patients remained recurrence-free.
One patient experienced grade 3 intismeran-related fatigue; no adverse events led to intismeran discontinuation.
No deaths were reported; analyses were descriptive, with no formal hypothesis testing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief on October 25, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Moderna publishes presentation on phase I intismeran study in resected pancreatic cancer

You may also like

Crypto prices